After notching a handful of regulatory approvals in the last four years, chimeric antigen receptor (CAR) T-cell therapies are beginning to deliver remarkable efficacy for cancer patients—albeit with some concrete limitations.
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of three oncology and cell therapy experts to its Scientific Advisory Board (SAB): Pamela Munster, MD; Caron Jacobson, MD, MMSc; and Evren Alici, MD, PhD.
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer
Exacis produces its iPSC-derived ExaNK™ cells using its proprietary mRNA-based cell reprogramming and gene editing technologies
Exacis has generated NK cells from iPSCs engineered using mRNA gene-editing technology to resist rejection by the patient’s immune system.
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced the addition of Dirk Huebner, MD, as its Chief Medical Officer.
Exacis Biotherapeutics, Inc., a development-stage immuno-oncology company working to harness the immune system to cure cancer, today announced its formation along with completion of in-licensing of certain technologies from Factor Bioscience, a leading cell sciences company.